Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INCALDR · Entity 154258 | Director · President and CEO | February 16, 2018 | February 21, 2018 |
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director · Chief Executive Officer | March 04, 2024 | March 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALDER BIOPHARMACEUTICALS INC
Report date February 16, 2018 · Filed February 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2028-02-15 | Direct | 200,000 |
Reported balance
After 2018-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-16 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
Bolt Biotherapeutics, Inc.
Report date March 04, 2024 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2034-03-03 | Direct | 235,000 |
Reported balance
After 2024-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-04 · Grant · Acquired 654,000 · Balance 235,000 F1: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2024 Filed Mar 6, 2024 18:28 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 654,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000950170-24-026997 · ownership.xml · derivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 654,000 shares Expires 2034-03-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 06, 2023 Filed Feb 6, 2024 18:08 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.78 | $1,955.00 |
DisclosureSEC source: 0001209191-24-002897 · doc5.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,859 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2023 Filed Feb 6, 2024 18:08 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.18 | $2,953.75 |
DisclosureSEC source: 0001209191-24-002897 · doc5.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,359 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:30 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 728,270 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-013674 · doc4.xml · derivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,270 Underlying: Common Stock · 728,270 shares Expires 2033-02-26 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 06, 2022 Filed Feb 7, 2023 21:53 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.18 | $2,953.75 |
DisclosureSEC source: 0001209191-23-007575 · doc5.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,859 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2022 Filed Feb 7, 2023 21:53 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.64 | $4,101.25 |
DisclosureSEC source: 0001209191-23-007575 · doc5.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,359 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 02:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 630,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-22-007519 · doc4.xml · derivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,000 Underlying: Common Stock · 630,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:20 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,500 | $20.00 | $30,000.00 |
DisclosureSEC source: 0001209191-21-008739 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 21:59 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008516 · doc4.xml · derivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/48th of the Shares will vest upon the Reporting Person completing each month of continuous service following February 4, 2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:39 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012043 · doc4.xml · derivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 18:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-010156 · doc4.xml · derivative · entry 3 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,181 Underlying: Common Stock · 30,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 18:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 30,000 | $25.03 | $750,756.00 |
DisclosureSEC source: 0001209191-17-010156 · doc4.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,172 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 18:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 30,000 | $1.65 | $49,500.00 |
DisclosureSEC source: 0001209191-17-010156 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:23 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-17-006429 · doc4.xml · derivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-01-26 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| November 30, 2016 Filed Jan 31, 2017 17:23 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 404 | $20.20 | $8,160.80 |
DisclosureSEC source: 0001209191-17-006429 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,172 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2016 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 18:17 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-16-149146 · doc4.xml · derivative · entry 3 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,181 Underlying: Common Stock · 10,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 18:17 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 10,000 | $25.16 | $251,605.00 |
DisclosureSEC source: 0001209191-16-149146 · doc4.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,768 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 18:17 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 10,000 | $1.65 | $16,500.00 |
DisclosureSEC source: 0001209191-16-149146 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 18:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,181 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-16-145134 · doc4.xml · derivative · entry 4 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,181 shares Expires 2017-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 18:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,700 | $31.55 | $85,189.05 |
DisclosureSEC source: 0001209191-16-145134 · doc4.xml · nonDerivative · entry 3 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,768 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.36 to $32.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 18:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 5,481 | $30.95 | $169,621.60 |
DisclosureSEC source: 0001209191-16-145134 · doc4.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,468 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.35 to $31.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 18:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 8,181 | $1.27 | $10,348.97 |
DisclosureSEC source: 0001209191-16-145134 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:36 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-16-140250 · doc4.xml · derivative · entry 3 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,181 Underlying: Common Stock · 10,000 shares Expires 2017-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:36 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 10,000 | $32.48 | $324,820.00 |
DisclosureSEC source: 0001209191-16-140250 · doc4.xml · nonDerivative · entry 2 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,768 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2015. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:36 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 10,000 | $1.27 | $12,650.00 |
DisclosureSEC source: 0001209191-16-140250 · doc4.xml · nonDerivative · entry 1 Schatzman Randall C · CIK 0001604763 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.